Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bextra Settlement Coming Soon: Industry Should Brace For Impact

Executive Summary

Pfizer's pending $2.3 billion settlement of an investigation into the promotion of Bextra (valdecoxib) sets a new record for a pharma company's liability in a health care fraud case, and begs the question of how big the political liability facing the industry will be as the latest wave of marketing cases reaches settlement

You may also be interested in...



Pfizer Sales Manager Gets Probation for Deleting Bextra Off-Label Data

A Pfizer sales manager was sentenced July 16 to six months of home confinement with electronic monitoring and three years of probation for obstruction of justice in the government's investigation of off-label promotion of Bextra (valdecoxib)

Pfizer Sales Manager Gets Probation for Deleting Bextra Off-Label Data

A Pfizer sales manager was sentenced July 16 to six months of home confinement with electronic monitoring and three years of probation for obstruction of justice in the government's investigation of off-label promotion of Bextra (valdecoxib)

Forest Celexa, Lexapro Off-Label Promotion, Kickbacks Alleged In DoJ Suit

Forest waged an extensive campaign to get doctors to prescribe its antidepressants Lexapro and Celexa for off-label use in children, while concealing data that Celexa was no more effective than placebo in pediatric patients, and carried an increased risk of suicide attempts, the Department of Justice claims in a 1complaint filed against the company

Related Content

Topics

UsernamePublicRestriction

Register

PS050610

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel